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Background
Sepsis affects over 26 million people worldwide each year result-
ing in a death every 3 to 4 seconds [1]. For every hour that an-
tibiotics are delayed after the first episode of hypotension, there
is a 7.6 % increase in the risk of mortality [2]. Thus, international
sepsis guidelines recommend the administration of broad
spectrum antimicrobial therapy within 1 hour of recognition [3].
In 2011, the New South Wales Clinical Excellence Commission
(CEC) developed the Sepsis Kills program including the Adult
Emergency Sepsis Pathway [4]. This pathway was introduced to
Emergency Departments (ED) and auditing of time to first antibi-
otics commenced. Belmont Hospital Emergency Department has
approximately 25000 presentations per year. In 2012, 163 pa-
tients were diagnosed with sepsis. Time to first antibiotics for
sepsis patients peaked at 254 minutes (Fig. 1). Discussion of
these results highlighted the need to develop education strat-
egies in order to reduce time to first administration of
antibiotics.
Materials and methods
Audits of the CEC Sepsis database [5] over 4 years included a
total of 769 patients. Collected data entered included: age, triage
time and category, clinical observations, time and amount of
intravenous fluid, time to first antibiotics, and diagnosis. The ta-
bles provided reflect median time to antibiotics. In 2012 a Clinical
Nurse Specialist from the ED was designated Sepsis Lead. Over
4 years, the Sepsis Lead worked collaboratively with clinical staff
to develop and implement several strategies to decrease time to
first antibiotics
Results
A multimodal approach strategy was adopted, which included: regu-
lar audits; targeted education programs for triage nurses and nursing
team leaders; the introduction of Sepsis September - a month dedi-
cated to sepsis awareness and education; and the Sepsis Road show.
These interventions were well received by Emergency staff. As a dir-
ect result time to first antibiotics was reduced to a median of 41 mi-
nutes (Fig. 2).
Conclusions
The collaborative effort between the Sepsis Lead and clinical staff
has produced a significant reduction in time to first antibiotics from
254 minutes to 41 minutes at last audit. The success achieved at Bel-
mont Hospital due to this multimodal approach strategy has the po-
tential to be translated globally. It also serves to highlight the
importance of the Emergency Nurse in early recognition and initi-
ation of treatment for sepsis.© The Author(s). 2016 Open Access This artic
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Background
Despite advances in diagnostic methods and antibiotic therapy,
community-acquired pneumonia (CAP) is still a major cause of mor-
bidity and mortality worldwide. Risk of CAP has been attributed to
pathogen virulence, host susceptibility and epidemiologic factors. A
significant number of patients with CAP develop severe complica-
tions, such as sepsis, acute respiratory distress syndrome (ARDS),
multiple organ dysfunction syndrome (MODS) and less fatal condi-
tions (pleuritis, empyema) and syndromes (acute respiratory failure
(ARF)). The variable clinical presentation of CAP suggests a genetic
predisposition.
Materials and methods
This study was conducted to establish the possible contribution
of functional gene polymorphisms in the oxidative stress related
genes to the development of community-acquired pneumonia
(CAP) complications. CAP subjects (n = 350) were genotyped for
16 polymorphic variants in the genes of xenobiotics detoxification
CYP1A1, AhR, GSTM1, GSTT1, ABCB1, redox-status SOD2, CAT,
GCLC, and vascular homeostasis ACE, AGT, AGTR1, NOS3, MTHFR,
VEGFa.
Results
The multilocus model which included six or more risk alleles in
the CYP1A1, GCLC, AGT and AGTR1 genes was associated with
pleuritis, empyema, acute respiratory distress syndrome (ARDS),
all pulmonary complications together and acute respiratory fail-
ure. Genetically mediated correlation between clinical conditions
in CAP patients is shown in Table 1. In silico analysis with Set
Distiller mode identified N-acetylcysteine (P = 1.08E-08) and oxy-
gen (P = 1.92E-06) as the best descriptors for the considered
gene set. Acute infections of the airways are associated with
oxidative stress, which enhances viscosity of bronchial mucus,
reduces the mucociliary clearance rate and expedites lung dis-
ease aggravation and progression. N-acetylcysteine is a well-
known mucolytic and antioxidant drug, an indirect precursor of
glutathione.
Conclusions
The results of the study indicate that pneumonia aggravation up to
destructive intrapulmonary complications and ARDS is mediated by
polymorphisms in oxidative stress-related genes.Table 1 (abstract P2). Correlation between clinical conditions in
stratified analysis based on the cumulative gene risk score
Number of the risk alleles
in the genes,
0-5 risk alleles 6-9 risk alleles
CYP1A1 (rs2606345 - T,
rs4646903 - T,
rs1048943 - A),
GCLC (rs17883901 - T),
AGT (rs699 - C),
AGTR1 (rs5186 - C)
PC - ARF r = 0.43 (P = 2.4E-07) r = 0.57 (P = 2.1E-18)
PSI - ARF r = 0.60 (P = 1.6E-06) r = 0.67 (P = 3.0E-16)
PC pulmonary complications, ARF acute respiratory failure, PSI pneumonia
severity index, r correlation coefficient, P P- value at two sided
significance levelP3
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Background
Currently there is little data on identification, management and out-
comes of patients with sepsis in developing countries. In low income
countries major concerns regarding accessibility to healthcare, limita-
tions due to costs, lack of resources and delayed presentations of
patients with sepsis make implementing protocols, based on de-
veloped countries patients profile difficult. Thus in Sub-Saharan
Africa there has been a widespread shift towards protocol devel-
opment that is cost effective and specific for the epidemiologic
and ecologic data.
Materials and methods
The aim of our study is to assess the efficacy of clinicians at a district
level hospital in the Western Cape at identifying and managing sep-
sis. Furthermore, we will assess the outcome of patients in terms of
in-hospital mortality and length of hospital stay given the above
management. A retrospective study design was applied when analyz-
ing data from the routine burden of disease audit done on a 3
monthly basis at Karl Bremer Hospital.
Results
The total sample size obtained was 70 patients. A total of 18/70
(26 %) patients had an initial triage blood pressure indicative of
sepsis induced hypotension however only 1/18 (5.5 %) of these
patients received an initial crystalloid fluid bolus of 30 ml/kg.
The median time for antibiotic administration in septic shock
was 4.65 hours. Further a positive delay in antibiotic administra-
tion (p value = 0.0039) was demonstrated. A total of 7/70 pa-
tients received no antibiotics in the first 24 hours of hospital
admission. Of these 7, 3 of these patients could be classified as
septic shock at presentation. All 3 patients died within 36 hours
of hospital admission. The data showed 8/12 (66 %) of patients
with septic shock received inappropriate amounts of fluids. The
in-hospital mortality for sepsis was found to be 4/24 (17 %), for
severe sepsis 11/34 (32 %) and a staggering 9/12(75 %) for sep-
tic shock. A positive association between in-hospital mortality
and the following was found:
Time to first dose antibiotic administration (OR = 1.07, P value =
0.027, 95%CI = 1.008-1.14). For every 1-hour delay in antibiotic ad-
ministration the chance of death increased by 7 %.
Source appropriate antibiotics (OR = 0.17, P value = 0.005, 95 % CI =
0.048-0.59). The chance of death amongst patients that received
source appropriate antibiotics is 83 % less than those who did
not.
Early appropriate intravenous fluid administration (OR = 0.33, P
value = 0.040,95 % CI = 0.11-0.95). Appropriate intravenous fluids
was associated with a 67 % reduction in in-hospital mortality.
Conclusion
The outcomes of the study concluded that there is room for improve-
ment by our clinicians with regards to appropriate identification and
management of patients with sepsis. Flawed management has inevit-
ably shown to have an impact on in-hospital mortality. Simple, cost ef-
fective measures that can implemented regardless of resources include
early appropriate antibiotics and early aggressive fluid therapy; with
the potential for an inordinate impact on mortality.
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Background
Recently, the Sepsis Severity Score (SSS) [1] was constructed to esti-
mate the probability of hospital mortality in severe sepsis and septic
shock patients. The aim of this study was to validate and compare
the performance of the SSS with the Acute Physiology and Chronic
Health Evaluation (APACHE) II-IV [2], Simplified Acute Physiology
Score (SAPS) II and SAPS 3 scores in predicting hospital outcome in
sepsis patients.
Materials and methods
A retroprospective analysis was conducted of prospectively collected
data from all consecutive sepsis patients admitted to the medical in-
tensive care unit of a tertiary university teaching hospital. The per-
formance of the severity scores was evaluated by discrimination,
calibration and overall performance.
Results
From a total of 931 patients, 802 patients (87.8 %) who had sep-
tic shock were enrolled. The hospital mortality rate was 43.9 %
and the mean age was 59.3 ± 21.5 years. The most common
sources of ICU admission were from the emergency room
(47.5 %), general wards (43.9 %), and transfers from other hospi-
tals (8.6 %). Mechanical ventilation was used in 808 patients
(88.5 %). Community-acquired infections accounted for 70.2 %.
The most common sources of infection were respiratory (49.1 %),
gastrointestinal (14.8 %) and primary bloodstream infections
(9.9 %). The median SSS was 80 (range 20–137). Hospital mortal-
ity by the SSS is demonstrated in Fig. 3.
The standard mortality ratios of observed mortality to predicted mor-
tality were between 0.81 and 1.1. The SSS presented good discrimin-
ation with an area under the receiver operating characteristic curve
(AUC) of 0.892. The performances of each severity scoring system are
shown in Table 2.
The discriminative performance of the SSS was not statistically
significant from the APACHE II (P = 0.07), SAPS II (P = 0.06) or
SAPS 3 (P = 0.11). However, the APACHE IV score showed the
best discrimination with an AUC of 0.948 and the overall per-
formance by a Brier score of 0.096. The AUC of the APACHE IV
score was statistically greater than the SSS (P < 0.0001), APACHE
II (P < 0.0001), APACHE III (P = 0.0002), SAPS II (P < 0.0001) and
SAPS 3 (P < 0.0001) (Fig. 4). The calibration of all scores was
poor (Hosmer-Lemeshow goodness-of-fit H test <0.05). The cali-
bration curves for the SSS and APACHE scores are presented in
Fig. 5.
Conclusions
The SSS provided good discrimination as well as the APACHE II, SAPS
II and SAPS 3 scores. However, the APACHE IV score had the best dis-
crimination and overall performance in our severe sepsis and septic
shock patients. The SSS needs to be adapted and modified with new
parameters to improve the performance.References
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Background
Sepsis in a public health problem and septic patients suffer
high mortality[1,2]. Few data are available about physicians'
knowledge and capacity to manage sepsis outside the Intensive
Care Unit (ICU) [3]. The physicians' knowledge about sepsis
could explain discrepancies in management between Emergency
Department (ED) and ward septic patients, who suffer a poorer
quality of care and a poorer outcome[4]. We aimed to assess
knowledge and ability to handle sepsis management through a
questionnaire.
Materials and methods
Observational, prospective, monocentric study during 6 months (May
to December 2015). A 26 questions sheet was distributed to all physi-
cians. Questionnaires were anonymous, included age, experience and
specialty. Questions involved definitions, epidemiology, outcome,
diagnosis and management of severe sepsis/septic shock. Eight ques-
tions out of 25 were core questions, and a 26th evaluated physicians'
self-appreciation of ability. Evaluation included levels of good, wrong
answers (WA) or "no knowledge" (NK) with specialties and self-
estimated ability. Physicians were compared as fellows or senior, and
specialties between "referent" (ED or Anesthesiologists/Intensivists vsothers). Statistical analysis was performed though Chi2, Fisher exact,
or Mann–Whitney tests.
Results
A hundred and thirty-two physicians (48.9 %), answered to the ques-
tionnaire: 34 ED or ICU/anesthesia physicians (26 %), 82 medical
specialists (62 %), 16 surgeons (12 %). Forty-five percent were fel-
lows. Median age was 29 years, median experience was 1 year after
diploma. Referent physicians expressed higher self-confidence (97 vs
52 %, p < 0.001). Nearly all of them knew about existence of inter-
national guidelines (97 %), whereas a third of others did not (68 %,
p = 0.001). Surgeons had poorer results and regarded themselves as
unable to handle sepsis. Fellows and senior physicians' knowledge
were equal (11 vs 10,8 % of wrong answers). Core questions revealed
flaws about definitions (22 % WA), sepsis outside the ICU (29 % WA/
NK), possible severity without hypotension (40.5 % WA/NK), import-
ance of lactatemia (24 % WA/NK), existence of guidelines (24 % WA/
NK), delay of antibiotic treatment (78 % agreed for up to a 6 h delay).
Knowledge about fluid expansion without hypotension was 88,5 %,
but 32 % failed about fluid choice.
Conclusions
Our study presents limits: it's monocentric with a small sample, with
no differences between intensivists or anesthesiologists, and some
questions may have been difficult to interpret. Moreover, it was
"medical-limited" and did not evaluate the nurses’ teams, a key fac-
tor. Nevertheless, it provides arguments to think that management
of sepsis could be improved through better knowledge outside the
ICU, that could trigger prompt recognition and management, or call
to specialized teams.
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Background
The induction of inflammatory responses by lipopolysaccharides
(LPSs, endotoxins) is achieved by the coordinate and sequential
action of four principal LPS-binding proteins: LPS-binding protein
(LBP), CD14, Toll-like receptor 4 (TLR4) and Myeloid differentiation
protein – MD-2 [1]. CD14, the cell surface receptor of monocytes
and neutrophils, is required for LPS activation of phospholipases,
protein tyrosine kinases, protein kinases A and C as well as MAP
kinases [2]. TLR4 independently of CD14 cannot mobilize all of
the adapter proteins that it requires for full signaling activity [3].
CD14 functional multiplicity provides the reason for their implica-
tion in target therapy of inflammatory response to LPS by devel-
opment of blocking monoclonal antibodies (mAbs) specific to
human CD14 [4] or TLR4 [5]. In the present study we have
examined CD14 involvement in endotoxin priming of human
Fig. 6 (abstract P6). Effect of anti-CD14 mAbs or IgG2a on fMLP-
triggered respiratory burst of control unprimed (a) and Re-LPS
primed human PML (b)
Fig. 7 (abstract P6). Comparison of the anti-CD14 mAbs effects on
fMLP-triggered respiratory burst of human PML primed by Re-LPS (a)
or S-LPS (b)
Critical Care 2016, 20(Suppl 3):357 Page 187 of 199polymorphonuclear leukocytes (PML) for respiratory burst trig-
gered by N-formyl-methionyl-leucyl-phenylalanine (fMLP).
Materials and methods
Human PML were isolated from heparinized blood of healthy volun-
teers by standard procedure and incubated with or without anti-
CD14 mAbs UCHM-1 or isotype-matched IgG2a for 30 min before
priming by LPS. Control cells and cells that had been preexposed to
mAbs or IgG2a were placed into chemiluminometer chambers con-
taining solution for luminol-enhanced chemiluminescence (CL) meas-
urement supplemented with autologous serum (2 %) and 0.01 mM
CaCl2. PML priming was achieved by addition of 100 ng/ml S- or Re-
LPS from Escherichia coli O55:B5 or JM103 followed by continuous
gentle shaking for 30 min at 37 °C. CL had been triggered by adding
of 1 μM fMLP and the light emission was recorded continuously for
20 min. Statistical significance was determined by applying the
Wilcoxon’s signed-rank date analysis. Differences were considered to
be significant when p < 0.05.
Results
LPS is known to be engaged by CD14 and then transferred to TLR4 [2,
6, 7]. To assess CD14 involvement in endotoxin priming of human PML
for fMLP-triggered respiratory burst we used the full anti-CD14 mAbs
containing Fc-regions. We have therefore examined the effect of anti-
CD14 mAbs as well as IgG2a on fMLP-triggered respiratory burst
of control LPS-unprimed PML. As described in Fig. 6a incubation
of PML with anti-CD14 mAbs decreased the level of fMLP-
triggered CL caused by reactive oxygen species (ROS) production
(p < 0.05). The same pattern was recorded when isotype-matched
IgG2a had been employed (p < 0.05) (Fig. 6a). It is not yet known
whether this inhibitory effect of the IgG2a’s Fc-regions on fMLP-
triggered ROS generation will be still maintained during PML
priming by endotoxins. When PML had been exposed to anti-
CD14 mAbs as well as to IgG2a and then primed by Re-LPS near
the same suppression of fMLP-triggered CL was detected (p <
0.05) (Fig. 6b). Compared to the control cells (75.29 ± 23.4 RU)
the average value of fMLP-triggered CL in Re-LPS primed PML
was increased up to 161.77 ± 49.4 RU (p < 0.05). However, after
exposition of PML to anti-CD14 mAbs or IgG2a followed by Re-
LPS priming the fMLP-triggered CL was reduced up to 112.55 ±
34.3 RU (by 30 %) or up to 126.90 ± 17.6 RU (by 22 %), respect-
ively (Fig. 6b). Since “quenching” effects of Fc-regions of full anti-
CD14 mAbs as well as isotype-matched IgG2a on fMLP-triggered
respiratory burst have been almost identical it is not possible at
the moment to make decision what is the real impact of F(ab')2-
regions of used anti-CD14 mAbs in PML priming by LPS. Some
indication on the impact of F(ab')2-regions in this process may
came from the comparison of anti-CD14 mAbs effect on PML
priming by different LPS-glycoforms, namely S- or Re-LPS. As fol-
lows from Fig. 7a and b the most pronounced inhibitory effect of
anti-CD14 mAbs on PML priming by S-LPS from E. coli has been
achieved (by 40 %). Especially role of CD14 in delivery of S-LPS
to TLR4 is well described [8].
Conclusions
LPS is known to be engaged by CD14 and then transferred to TLR4
[2, 6, 7]. To assess CD14 involvement in endotoxin priming of human
PML for fMLP-triggered respiratory burst we used the full anti-CD14
mAbs containing Fc-regions. We have therefore examined the effect
of anti-CD14 mAbs as well as IgG2a on fMLP-triggered respiratory
burst of control LPS-unprimed PML. As described in Fig. 6a incuba-
tion of PML with anti-CD14 mAbs decreased the level of fMLP-
triggered CL caused by reactive oxygen species (ROS) production (p
< 0.05). The same pattern was recorded when isotype-matched IgG2a
had been employed (p < 0.05) (Fig. 6a). It is not yet known whether
this inhibitory effect of the IgG2a’s Fc-regions on fMLP-triggered ROS
generation will be still maintained during PML priming by endo-
toxins. When PML had been exposed to anti-CD14 mAbs as well as
to IgG2a and then primed by Re-LPS near the same suppression of
fMLP-triggered CL was detected (p < 0.05) (Fig. 6b). Compared to the
control cells (75.29 ± 23.4 RU) the average value of fMLP-triggered CL
in Re-LPS primed PML was increased up to 161.77 ± 49.4 RU (p <
0.05). However, after exposition of PML to anti-CD14 mAbs or IgG2a
followed by Re-LPS priming the fMLP-triggered CL was reduced upto 112.55 ± 34.3 RU (by 30 %) or up to 126.90 ± 17.6 RU (by 22 %), re-
spectively (Fig. 6b). Since “quenching” effects of Fc-regions of full
anti-CD14 mAbs as well as isotype-matched IgG2a on fMLP-triggered
respiratory burst have been almost identical it is not possible at the
moment to make decision what is the real impact of F(ab')2-regions
of used anti-CD14 mAbs in PML priming by LPS. Some indication on
the impact of F(ab')2-regions in this process may came from the
comparison of anti-CD14 mAbs effect on PML priming by different
LPS-glycoforms, namely S- or Re-LPS. As follows from Fig. 7a and b
the most pronounced inhibitory effect of anti-CD14 mAbs on PML
priming by S-LPS from E. coli has been achieved (by 40 %). Especially
role of CD14 in delivery of S-LPS to TLR4 is well described [8].
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Background
Bacterial pneumonia is a life threatening condition causing acute lung
injury (ALI) leading to development of sepsis depending on the inva-
siveness of the bacteria and host immune status. This present study
was designed to find out the protective immunomodulatory action of
macrolide antibiotic (i.e. clarithromycin) in mouse model of pneumonia
induced by K. pneumoniae B5055.
Materials and Methods
Pneumonia was induced by intranasal instillation of Klebsiella pneumoniae
B5055 (104 cfu/ml) by holding the mice in upright position without any an-
aesthesia. Experimental animals were divided in two groups (i.e. Group A;
control (oral saline), Group B; clarithromycin (30 mg/kg/day/os). At desig-
nated period of time (1, 2, 3, 5 and 7 days) mice were eutha-
nized by cervical dislocation and lungs were harvested and
homogenized in 1 ml of sterile normal saline under sterile condi-
tions. The lung homogenate was used for measuring bacterial
load, malondialdehyde (MDA), nitric oxide (NO) and myeloperoxi-
dase (MPO) and pro-inflammatory (i.e. IL-1α, IL-6, TNF-α) anti-
inflammatory (i.e. IL-10) cytokine levels in lungs. Histopathological
examination of the lungs was also carried out along with lung al-
veolar macrophage function (i.e. macrophage spreading and
phagocytosis) assays.
Results
Clarithromycin treatment led to the significant (p < 0.05) reduction
in pulmonary neutrophil infiltration along with significant (p <
0.05) decrease in other markers of inflammation (TNF-α, IL-α, IL-6,
MDA, NO and MPO) associated with acute tissue injury or inflam-
mation. The increase in bacterial clearance in lungs of mice
treated with clarithromycin was associated with significant (p <
0.05) increase in macrophage spreading as well as their phago-
cytic potential (i.e. phagocytic uptake and intracellular killing) of
alveolar macrophages.
Conclusions
Clarithromycin has a great potential as an immunomodulatory anti-
biotic during K. pneumoniae B5055 induced pneumonia associated
acute lung inflammation or injury (ALI).
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Experimental models have shown that histones are involved in the pro-
gression of sepsis and may be candidate prognostic biomarkers. There are
limited prospective cohort studies of suspected septic patients aimed at
determining the risk associated with increased level of histones to their
progression to severe sepsis. To address this, we (1) developed an IgY-
based immunoassay that can detect and quantify blood histone levels; (2)
tested whether there is a difference in histone levels among septic and fe-
brile patients that present in the emergency room; and (3) tested whether
there is an association between histone levels in serum and the progres-
sion of patient to developing hypotension (sBP <90 mmHg), azotemia,
(creatinine> 2.0 mg/dL (176.8 μmol/L)) or thrombocytopenia (platelet
count < 100,000/μL) using the developed IgY-based immunoassay.
Materials and methods
An indirect ELISA was developed for detecting human histones that used
polyclonal immunoglobulin Y (IgY) extracted from eggs laid by calf
histone-challenged chickens as a primary antibody. Chickens were inocu-
lated with calf histones and the IgY from eggs were extracted by means
of a delipidation, salt precipitation and affinity chromatography.
To determine its clinical utility as a prognostic kit, a prospective cohort study
of 4 febrile patients and 21 septic patients seeking consult at the emergency
room were enrolled based on the inclusion criteria. Higher total histone
levels measured by immunoglobulin Y was then determined if it was related
to the development of hypotension, azotemia or thrombocytopenia.
Results
The limit of detection of this IgY-based immunoassay was determined
to be 2036 pg/mL. Comparison of histone levels between 4 febrile pa-
tients, and 21 septic patients within 3 days of admission in the hospital
showed that septic patients have significantly higher (p = 0.0314) levels
of histones as compared to febrile patients (Fig. 8).
In this cohort, those that developed hypotension, azotemia or
thrombocytopenia during their hospital stay have higher levels of
histones upon admission (p = 0.0257) compared to those that did not
(Fig. 9). Receiver operator curve analysis showed that at 2101 pg/uL
(Fig. 10), likelihood ratio was 3.545 which had an estimated sensitiv-
ity (76.9 %), specificity (81.81 %), PPV (83.33), and NPV (75 %) (p =
012, Chi square test). At a cutoff of <2081 pg/uL, likelihood ratio was
5.909 of sensitivity (45.45 %) and specificity (92.31 %).
Conclusions
Histone levels may be predictive to the progression of defined
clinical parameters related to worse outcomes in septic patients.
Fig. 9 (abstract P9). Patients that progressed into having
hypotension, azotemia or thrombocytopenia have significantly
higher histone levels than those that did not. In this cohort, those
that progressed to severe sepsis (Mean = 2110, 95 % CI 2095–2125)
have significantly higher levels of histones in their blood (P < 0.05,
two-tailed t-test), as compared to those who did not progress
(Mean = 2084, 95 % CI 2073–2096)
Fig. 10 (abstract P9). Receiver-Operating Characteristic (ROC)
Curves for Prognosticating those that will progress into severe sepsis
among the septic and febrile patients. The AUC is 0. 0.7727 (95 % CI,
0.5782 to 0.9672)
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Background
Acute lung injury (ALI) is an important cause of morbidity and mortality
in critically ill patients. Although the condition has many etiologies,
pneumonia and sepsis are leading triggers. Age is a major determinant
of clinical outcome, and there are age-dependent alterations in the re-
sponses to pulmonary challenge that can trigger kidney inflammation
(a precursor of chronic kidney disease) and higher mortality rates.Staphylococcus aureus infection is a frequent cause of pneumonia, es-
pecially in elderly patients. To develop a better understanding of the
pathophysiology, and assist in defining future targets, we developed a
lung model of staphylococcal pneumonia in rodents. Using this model
we have examined inflammatory responses, hemodynamics, and car-
diac proteasome activation, neutrophil trafficking in pulmonary inflam-
mation, and age-related changes [1–3]. Here we examined renal
inflammation following pulmonary challenge.
Materials and methods
C57Bl6 Mice (8–10wks, n = 6-8/group) were challenged intratra-
cheally with staphylococcal cell wall components, lipoteichoic
acid (LTA), and peptidoglycan (PGN): (0.2 μg + 0.66 μg); (30 mg
+ 100 mg); (150 mg + 500 mg); or saline alone. Pulse oximetry
was performed on awake animals before challenge and immedi-
ately prior to euthanasia. At 6, 24 or 72 hrs post challenge, ani-
mals were euthanized, bronchoalveolar lavage (BAL) performed,
and tissues harvested. Concentrations of plasma and BAL cyto-
kines were assessed by ELISA. The left kidney was fixed for
histological analysis, and the right kidney was assessed for cyto-
kine mRNA by qPCR, cytokine protein using ELISA, and activity
of specific proteasome subunits by ProCISE [4].
Results
BAL from LTA/PGN challenged mice showed significant increases in
neutrophils, total protein, IL-6, KC, MCP-1, TNFa and MIF as in previ-
ous studies. Additionally, while there was no LTA or PGN detected in
the plasma, LTA/PGN challenged mice had increased plasma concen-
trations of IL-6, IL-1b, KC and TNFa. In renal tissue, there were time
and concentration dependent changes in IL1b, IL-6, TNFa, IP10, and
MCP-1 and an increase in proteasome b5 subunit activity.
Conclusions
Even in these young animals pulmonary challenge induced signifi-
cant inflammatory changes within the lung, blood and kidney. Not-
ably, in the kidney there was increased activity of proteasome b5, a
regulator of IκB/NFκB activation and signaling pathways. Our recent
study uncovered a time dependent, NF-kB switch that regulates tran-
sition from endothelial barrier injury to repair [5]. If we can define
changes in the injury-to-repair phase in the kidney, we may reveal
specific targets for therapeutic manipulation in a clinically relevant
time frame to improve outcome from ALI associated renal involve-
ment, particularly in the older individual.
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Fig. 11 (abstract P11). Cathelicidin is upregulated after cecal-
ligation and puncture induced sepsis in 129X1/SvJ (cnlp+/+) mice
from which total RNA and protein were collected from distal ileums
over a period of time for (a) real time PCR targeting clnp for
mCRAMP. Genetic knockout of cnlp led to (b) reduced survival, (c)
higher sepsis severity score and (d) increased bacterial DNAemia
upon experimental sepsis. Error bars represents standard error of the
mean. P < 0.05 denotes statistical significance, Mann–Whitney U-test
Fig. 12 (abstract P11). Effects of cecal-ligation and puncture (CL) or
sham surgery (Sh) on (a-d) the expression of mucin genes MUC1-4
and (e) acid mucin in distal ileum of cathelicidin wildtype (WT) or
knockout (KO) mice at 24 h after CL as determined by quantitative
real-time PCR and Alcian blue perioidic acid Schiff reaction, respect-
ively. (f) The number of acid-mucin producing globlet cells per villus
was compared. Error bars represent standard error of the mean
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Accumulating evidence suggests that the intestinal barrier func-
tion is impaired during systemic inflammation as in sepsis. Animal
models of sepsis revealed several ileal pathological changes.
These include epithelial apoptosis, disruption of tight junctions
and increased intestinal permeability [1,2]. The impaired gut bar-
rier function may increase the risk of bacterial translocation from
the gut lumen to the bloodstream, aggravating systemic inflam-
mation. The molecular mechanism associated with this phenotype
remains largely unknown. Cathelicidin represents one of the most
important classes of antimicrobial peptides in mammals. In
addition to bactericidal property, this peptide inhibits endotoxin-
induced pyroptosis of leukocytes, suppresses the release of in-
flammatory mediators and protects endothelial cells from apop-
tosis [3–5]. In this study, we aimed to investigate the role of
murine cathelicidin-related antimicrobial peptide (mCRAM), a ro-
dent antimicrobial peptide analogous to human LL-37, in main-
taining gut barrier function in sepsis.
Materials and methods
129X1/SvJ mice that were wild type (cnlp+/+) or deficient for
cathelicidin (cnlp−/−) were used. Polymicrobial sepsis was
induced by cecal-ligation and puncture (CLP) [6]. Animals were
divided into four groups: cathelicidin wild type and knockout
mice receiving either CLP or sham surgery. At 24 h, blood and
ileal tissues were harvested for total bacterial DNA quantifica-
tion, immunoblotting and histological staining. The survival
rates and septic severity were recorded every 12 hours until
seven days after the surgery. Sepsis morbidity was evaluated by
Murine Sepsis Severity (MSS) score [7]. At 20 h after CLP or
sham surgery, the animals were orally fed with 4 kDa
fluorescein-dextran. Three hours later, serum was harvested and
fluorescence was measured.
Results
Knocking out cnlp gene has significantly increased septic severity
and reduced 7-day survival of 129X1/SvJ mice. Real time PCR target-
ing bacterial 16S rDNA revealed that total bacterial DNA load in-
creased more than threefold (Fig. 11).
Without cathelicidin, the expression of mucus has also reduced
considerably, as revealed by Alcian blue periodic acid Schiff reac-
tion and RT-PCR targeting MUC1, MUC2, MUC3 and MUC4 genes
(Fig. 12). Immunoblotting revealed cleavage of caspase 3 and
PARP involving in apoptosis (Fig. 13). Consistently, confocal mi-
croscopy using TUNEL staining identified greater number of
puncta per villus. Deletion of cnlp gene increased ileal permeabil-
ity to 4kD Fluorescein-labelled dextran, accompanied with re-
duced expression of tight junction proteins claudin-1 and
occludin (Fig. 14).
Conclusions
This study demonstrated the critical role of cathelicidin in maintain-
ing gut barrier integrity in polymicrobial sepsis. This may partially ex-
plain the association between lower LL-37 and higher mortality in
septic patients [8].
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Fig. 13 (abstract P11). Increased apoptosis was detected in
cathelicidin-knockout (cnlp−/−) mice compared to -wild type mice
(cnlp+/+) after CL-induced sepsis as demonstrated by (a) immuno-
blotting for cleaved caspase-3 and poly ADP ribose polymerase
(PARP), and (b) TUNEL staining. Quantification was shown, for TUNEL,
as (c) number of punta per villus. All specimens were collected at
24 hr after CL or Sham surgery. Error bars denote standard error of
the mean. P < 0.05 denotes statistical significance, Kruskal-Wallis test
Fig. 14 (abstract P11). Deletion of cnlp increased ileal permeability
as evidenced by (a) increased serum concentration of FITC-labeled
dextran 4kD (FD-4) at 3 hr after oral garvage following CL. (b) The
protein level of occludin and claudin-1 was determined by immuno-
blotting. Error bars denote standard error of the mean
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Critical Care 2016, 20(Suppl 3):P13Background
To date, there is no standard diagnostic test to identify septic
patients, although early identification is necessary to improve their
outcome [1]. We sought to identify novel biomarkers by studying the
enzymatic activity of the proline-specific peptidases dipeptidyl pep-
tidase 4 (DPP4), prolyl carboxypeptidase (PRCP), fibroblast activation
protein α (FAP) and prolyl oligopeptidase (PREP) in the plasma of 32
controls and 40 patients with septic shock on days 1, 3, 5 and 7.
Materials and methods
Enzymatic activity measurements were done using in-house developed
specific assays [2–4]. On the same days, inflammatory (e.g. TNF-α, IL-6) ,
hemodynamic (e.g. mean arterial pressure, pulse) and metabolic param-
eters (e.g. bilirubin, lactate) were measured as well. The data was used
to generate receiver operating characteristic (ROC) curves and to iden-
tify associations. A survival analysis (up to 90 days) was also performed.
Results
Significant differences between the control group and the patients with
septic shock could be found for all four enzymes. PREP and PRCP showed
a higher enzymatic activity on day 1 compared to the controls (p≤ 0.05
and p≤ 0.01, respectively). FAP and DPP4, on the other hand, were both
much lower in the patients group on all studied time points (p≤ 0.001).
PREP, FAP and DPP4 showed to be very good in discriminating cases
from controls with area under the curve (AUC) values of 0.91 (CI: 0.85-
0.99), 0.96 (CI: 0.92-1) and 0.94 (CI: 0.89-0.99), respectively. PRCP had a
lower predicting value with an AUC of 0.69 (CI: 0.58-0.82). A nominally sig-
nificant association was observed between survival and the DPP4 enzym-
atic activity at day 1 (p≤ 0.05), with a higher DPP4 enzymatic activity
being associated with an increase in survival. Several interesting positive
associations, such as PRCP with lactate, PREP with IL-1 receptor antagonist
and PREP with intestinal fatty-acid binding protein, were identified. PRCP
and PREP were also associated with the dosage of noradrenalin adminis-
tered to maintain an acceptable mean arterial pressure.
Conclusions
DPP4, FAP and PREP showed to be good in discriminating between con-
trols and cases and should be further explored as possible candidate bio-
markers for sepsis. The associations found also warrant further research.
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Background
The systemic inflammation represents a primary injury to the intestinal
epithelium structure. In acute phase, the massive production of inflam-
matory mediators (cytokines and nitric oxide) contributes to the
intestinal permeability, bacterial translocation and tight junction re-
arrangement. During the past decades, the clinical administration of
glucocorticoids has been widely discussed and the Surviving Sepsis
Campaign’s recommendation is the low-dose treatment for those
Table 3 (abstract P16). Clinical characteristics of septic patients with
and without features of MAS
Biochemical Profile
Septic Patients with






Ferritin, ng/ml, 0 hr
mean (sd, median,








IL-18, pg/ml, 0 hr
mean (sd, median,









IFN-γ, pg/ml, 0 hr
mean (sd, median,








IL-1β, pg/ml, 0 hr
mean (sd, median,
range) [95 % CI]










90-day mortality, % 61.0 28.1 <0.0001
*The p values represent a comparison between the patients with features of
macrophage activation syndrome (MAS) and the patients without features of
MAS. We used Fisher’s Exact test for categorical measures and the Mann–
Whitney U test for continuous and non-normally distributed measures
Critical Care 2016, 20(Suppl 3):357 Page 192 of 199patients refractory to vasopressor therapy. Our aim was to investigate
the possible role of dexamethasone on lipopolysaccharide (LPS)-in-
duced intestinal epithelial barrier dysfunction. Furthermore, we evalu-
ated its ability to modulate the inflammatory response and also the
expression of proteins of the intestinal tight junctions.
Materials and methods
To conduct these experiments, male rats had their jugular vein cannu-
lated for endotoxin administration, one day before the experiment. Rats
were pre-treated with dexamethasone (synthetic glucocorticoid; 0.1 or
1 mg/kg, intraperitoneal) before LPS administration (1.5 mg/kg, intra-
venous). At 6 h after endotoxemia induction, the intestinal permeability
was evaluated by injecting FITC-dextran 4 kDa in the ileum, mesenteric
lymph nodes were collected for microbiological analysis and also cyto-
kines were quantified in the plasma and intestinal mucosa by ELISA
technique. Additionally, the integrity of the tight junctions was deter-
mined by transmission electron microscopy, histological analysis, the
expression of tight junction proteins (occludin, claudin-1, claudin-2,
junctional adhesion molecule-A) as well as their localization.
Results
Our results demonstrated that dexamethasone administration reduces
the LPS-induced permeability in the ileum and prevented the bacterial
translocation to the mesenteric lymph nodes. The plasma and mucosa
concentrations of TNF-α, IL-1β, IL-6, IL-10 and IFN-γ were significantly
reduced in dexamethasone-treated rats. Furthermore, treatment with
dexamethasone reverted the LPS-induced epithelial barrier dysfunction,
increasing the expression of occludin and claudin-1, reducing the
claudin-2 cleavage and also the localization of these proteins at the ap-
ical portion. Moreover, the histological damages and the morphology
of the tight junctions were preserved by the dexamethasone adminis-
tration, therefore reducing their opening induced by endotoxemia.
Conclusions
Together these results suggest a protective role for dexamethasone
preventing the intestinal barrier dysfunction induced by systemic in-
flammation, possibly modulating the inflammatory response. Further-
more, these experimental findings reinforce the Surviving Sepsis
Campaign’s recommendation for the administration of low gluco-
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Background
Shakoory and colleagues performed a post hoc analysis of a ran-
domized clinical trial of anakinra, an interleukin-1 receptor antag-
onist [1], and reported that severe sepsis patients with features
of macrophage activation syndrome (MAS), defined by the com-
bined presence of hepatobiliary dysfunction and disseminated
intravascular coagulation, represented 5.6 % of the severe sepsis
population. Additionally, anakinra, in comparison with placebo,
reduced 28-day mortality (34.6 % vs 64.7 %; p < 0.05) in a subset
of patients with features of MAS [1]. Based on these findings, we
hypothesized that the Protocolized Care for Early Septic Shock
(ProCESS) trial [2] would contain a similar proportion of septic
patients with features of MAS and a similar mortality rate. We
further hypothesized that MAS patients would have elevatedcirculating biomarkers related to macrophage activation, including
ferritin, interleukin-18 (IL-18), interleukin-1β (IL-1β), and interferon-
γ (IFN-γ).
Materials and methods
We selected all patients with features of MAS and age-matched con-
trols without features of MAS from the ProCESS trial. Concentrations of
circulating ferritin, IL-18, IL-1β, and IFN-γ were measured in plasma
samples collected on day 1, and mortality was assessed at hospital dis-
charge and at 90 days. The MAS patients were further stratified accord-
ing to their circulating ferritin levels, and a threshold of 1200 ng/ml
was established based on the upper limit of the 95 % confidence inter-
val for the mean ferritin concentration in MAS survivors.
Results
Of the 1341 ProCESS subjects, 82 exhibited features of MAS (6.1 %). In-
hospital and 90-day mortality rates were higher in the MAS patients
than the non-MAS patients (42.7 % vs 9.8 % and 61.0 % vs 28.1 %; p <
0.05). As outlined in Table 3, MAS subjects showed higher circulating
ferritin, IL-18, and IL-1β concentrations (p < 0.05). Approximately 27 %
of septic patients with features of MAS had ferritin concentrations
greater than 1200 ng/ml. Interestingly, these patients had higher in-
hospital mortality (63.6 %) and 90-day mortality (72.7 %), as well as
higher IL-18, IL-1β, and IFN-γ concentrations compared to the septic pa-
tients without MAS (p < 0.05) (Table 4).
Conclusions
Post hoc analysis of ProCESS patients illustrated that features of MAS
are relatively uncommon but lethal in severe sepsis. Septic patients
with features of MAS and ferritin levels greater than 1200 ng/ml had
the highest mortality and increased IL-18, IL-1β, and IFN-γ concentra-
tions compared to non-MAS septic patients, making this an attractive
subset to target in future anti-inflammatory agent trials.
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Table 4 (abstract P16). Clinical characteristics of septic patients with
features of MAS and ferritin concentrations >1200 ng/ml vs septic







Ferritin >1200 (n = 22)
P
value*
Ferritin, ng/ml, 0 hr
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IFN-γ, pg/ml, 0 hr
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IL-1β, pg/ml, 0 hr
mean (sd, median,











90-day mortality, % 28.1 72.7 0.0003
*The p values represent a comparison between the patients without features
of MAS and the patients with features of MAS and ferritin concentrations
>1200 ng/ml. We used Fisher’s Exact test for categorical measures and the
Mann–Whitney U test for continuous and non-normally distributed measures
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Background
Patients after esophagectomy are prone to develop sepsis due to
pneumonia, anastomotic leakage, or wound infection. A new diag-
nostic test (SeptiCyte LAB) that measures the expression of fourblood gene biomarkers has diagnostic utility in distinguishing sepsis
from SIRS [1]. However, test performance in the immediate postoper-
ative setting has not been investigated.
Materials and methods
We studied patients undergoing esophagectomy in two Dutch uni-
versity hospitals from 2011 to 2013 who had developed a complica-
tion requiring ICU (re)admission within 30 days. Blood was collected
postoperatively and when a complication occurred. After RNA extrac-
tion, samples were analyzed on an Applied Biosystems® 7500 fast Dx
Real-Time PCR instrument. SeptiCyte LAB results (a score, range 0–
10) were categorized into four probability bands according to the
manufacturer's specification.
Results
Among 384 patients 113 (29 %) subjects had developed at least one
complication and were thus eligible for study inclusion; paired sam-
ples (i.e., both a direct postoperative and follow-up sample) were
available for 71 (63 %) of these. Sample preparation or processing is-
sues resulted in exclusion of 4 pairs, leaving 67 (59 %) patients for
analysis (Table 5).
Five (7 %) patients had active infection during postoperative
sampling, and 55 (82 %) on the day of their first complication.
SeptiCyte results were highly variable immediately after surgery
and at follow-up (Fig. 15), but scores increased significantly as
complications evolved (median 2.7 (IQR 1.6-3.4) versus 7.3
(5.7-8.7); p < 0.001). Importantly, samples taken during infection
yielded higher scores then specimens taken at onset of a non-
infectious complication (median 7.3 (5.7-8.7) versus 5.2 (4–6.3);
p < 0.001).
Considering all 134 samples separately, 45 were classified as 'sep-
sis not likely' based on a SeptiCyte score <3.1; among these, we
observed 2 cases of confirmed infection (false negative rate 4 %).
Likewise, among 89 events with a score >3.1, infection was ruled-
out or never clinically suspected in 33 cases (false positive rate
37 %). The incorporation of SeptiCyte LAB results markedly im-
proved the performance of SIRS criteria in classifying confirmed
infections (c-statistic 0.86 (95%CI 0.80-0.93) versus 0.97 (95%CI
0.94-0.99); p < 0.001). However, a final diagnosis of infection could
not be made with certainty on 21 occasions (including two post-
operative samples), which precluded formal estimation of test
characteristics.
Conclusion
SeptiCyte LAB is a novel sepsis biomarker which may have clin-
ical utility in monitoring patients at high risk for postoperative in-
fections, but its diagnostic value in this setting has to be further
evaluated.
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Table 5 (abstract P17). Patient characteristics by infection status at the
time of a first postoperative complication (n = 67)






(N = 12) (N = 19) (N = 36)







Charlson Comorbidity Index 5.5 (0.0,
6.9)
6.4 (0.0, 6.4) 6.4 (5.1, 9.5) 0.15
SOFA score 5.0 (2.0,
6.0)
5.0 (3.0, 6.0) 6.0 (4.0, 8.0) 0.24
Complication onset, days after surgery 3.0 (2.0,
4.0)
5.0 (3.0, 11.0) 6.5 (3.0, 8.0) 0.09




2.0 (1.0, 4.0) 8.5 (4.5, 16.5) <0.001
Hospital mortality 1 (8 %) 1 (5 %) 12 (33 %) 0.03
SIRS criteria
T > 38 °C or T < 36 °C 4 (33 %) 7 (37 %) 13 (36 %) 0.98
WBC <4 or >12 (109/ml) 4 (33 %) 10 (53 %) 23 (64 %) 0.18
Respiratory rate >20/min, PCO2 < 32 mmHg or
mechanical ventilation
5 (42 %) 11 (58 %) 31 (86 %) 0.01
Heart rate >90/min 6 (50 %) 13 (68 %) 28 (78 %) 0.19
The likelihood of infection was based on post hoc physician assessment using
validated definitions [2]. Patients considered to have 'possible' infection were
classified as undetermined; patients considered to have 'probable' or 'definite'
infection were classified as confirmed. *These include 5 patients initially
treated with antibiotics in whom infection was later ruled out, and 7 patients
in whom infection was never clinically suspected
Data show medians (Q1 – Q3) or n (%). SOFA = Sequential Organ Failure
Assessment, SIRS = Systemic Inflammatory Response Syndrome, T =
Temperature, WBC =White blood cell count
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Fig. 15 (abstract P17). Distribution of SeptiCyte LAB scores in
samples taken immediately after surgery and at onset of a
postoperative complication
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Background
The Third International Consensus definitions for sepsis aimed to
improve the discrimination between sepsis and uncomplicated infec-
tions [1]. Our goal was to assess the construct and criterion validity
of the new definitions in a cohort of ICU patients with infection.
Methods
We analyzed ICU patients with suspected infection who were enrolled
as part of a prospective cohort study in the Netherlands between June
2011 and April 2015 [2]. Infections were classified as either present at
admission or newly-acquired in the ICU (onset >48 hours). Sepsis and
septic shock were defined according to both old and updated criteria
[1,3]. The apparent incidences of sepsis and septic shock according to
both definitions, and associated hospital mortality rates were com-
pared. In addition, we explored minor variations in the timing of diag-
nostic criteria relative to infection onset, and inclusion of lactate for the
definition of septic shock. Sepsis status was added to a baseline logistic
model (including age, gender, race and chronic comorbidity) to evalu-
ate the value of the sepsis-3 criteria in predicting mortality.
Results
Among 1582 included patients, 1081 had suspected infection at admis-
sion; 1020 (94 %) and 391 (36 %) of these fulfilled sepsis and shock cri-
teria according to the sepsis-3 definitions, compared to 1044 (97 %)
and 290 (27 %) for the old definitions (agreement 92 % and 81 %, re-
spectively). Mortality was 28 % (95%CI 25–31) in patients meeting
sepsis-3 criteria compared to 27 % (95%CI 25–30) for new definitions,
this was 42 % (95%CI 37–47) and 50 % (95%CI 45–56) for septic shock
(Figure 1). Among 501 patients with ICU-acquired infection, 298 (59 %)
and 141 (28 %) patients as compared to 497 (98 %) and 96 (19 %) pa-
tients fulfilled the new and old definitions, respectively (agreement
60 % and 73 %). Mortality in sepsis was 38 % (95%CI 33–44) and 35 %
(95%CI 31–39) and was 50 % (95%CI 41–58) versus 69 % (95%CI 59–78)
for septic shock. Although the observed incidence of sepsis and septic
shock varied widely by both variations in the time window used for de-
fining sepsis and inclusion of lactate for defining shock, neither modifi-
cation impacted mortality (Figure 1). Sepsis-3 had small, but statistically
significant incremental value in predicting mortality in patients with in-
fection at admission (AUC 0.62 versus 0.60;p = 0.0002), nearly equal the
old sepsis definition in this respect (AUC 0.61 versus 0.60;p = 0.0338).
Conclusion
Agreement between new and old sepsis definitions was higher in infec-
tions at admission than in ICU-acquired infections. Mortality was similar
using the various sepsis definitions. Sepsis-3 had no clinical relevant
additive value in predicting mortality infections at admission.
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Table 6 (abstract P19). Dynamic of PhCAs, lactate and SOFA
depending on the outcome, Me (25-75 %)
Characteristic Survived patients (n = 30) Died patients (n = 15)
On ICU
admission




After 48 hrs. of
ICU treatment





1,3 (1,0-2,1) 1,2 (0,9-1,7) 3,1 (2,5-3,9) 3,8 (2,2-10,4)
SOFA, scores 2 (1–5) 1 (0–3) 5 (4–8) 8 (7–10)
Fig. 16 (abstract P19). Prognostic value of PhCA and lactate
clearances in high-risk patients with acute abdomen after surgery
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Introduction
Metabolites of aromatic amino acids - phenylcarboxylic acids (PhCAs)
- significantly increased in critically ill patients with infection, espe-
cially with sepsis [1] and associated with mortality [2, 3]. They have
demonstrated good predictive ability in patients with different crit-
ical illness [3, 4]. Unfortunately, accurate prediction does not save the
patient's life. We need better criteria for evaluating of treatment effi-
ciency in patients with infection. This work is our first step in the
development of laboratory monitoring based on PhCA clearance.
Methods
High-risk patients with median age 60 (IR 53–74) years with acute abdo-
men (n = 45, male 51 %) were admitted to the ICU immediately after
emergency surgery. Acute abdomen development was associated with
intestinal perforation (n = 26) and/or acute intestinal obstruction (n = 19).
Serum samples were collected on the first and the third days of treat-
ment in the ICU. The total level (C) of three PhCAs (phenyllactic, p-
hydroxyphenyllactic and p-hydroxyphenylacetic acids) was measured
using previously described gas chromatography methodology [5]. Lactate
concentration (C) and SOFA scores were registered. PhCA and lactate
clearance was calculated as followed: [(Cfirst-Cthird)/Cfirst]x100%. The effi-
ciency of treatment was judged based on the ICU outcome. Statistical
processing was performed using IBM SPSS Statistics 22 program.
Results
The results were divided into two sub-groups and were presented as
medians with 25-75 % interquartile range depending on the out-
come (Table 6).
PhCA and lactate clearances correlated with changes in SOFA scale
rs: 0.655 and 0.531 respectively, p < 0.05. Logistic regression equation
was formulated for each of the clearances (−2log; p): PhCAs
(35.106;<0.001), lactate (52.252;0.025). So the proportion of true pre-
dicted solutions with the usage of the model based on PhCA clear-
ance was 82 %, while lactate model gave only 73 %. Logistic
regression determined that the treatment should be considered as
effective if PhCA level reduced by 27 % or more on the third day (in
this case risk of fatal outcome is lower than 10 %) and not effective
if PhCA level increased more than 60 % from the initial level (as evi-
denced by a high risk of mortality >30 %). The prognostic value
based on the clearance was more significant for PhCAs [AUC 0,862
(p < 0.001)] then for lactate [AUC 0.667 (p = 0.071)], Fig. 16.
Conclusions
Essentially new data suggest a promising use of PhCA clearance for
the assessment of the ICU treatment efficiency.
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Background
The cholesteryl-ester transfer protein isoform exclusively expressed in
the small intestine (CETPI) and present in human plasma, although
discovered by our group a few years ago, it had been waiting for a
functional description and a plausible role of physiological relevance
[1]. Unlike the cholesteryl-ester transfer protein (CETP), CETPI does
not present exon 16 and 54 bases contained in intron 15 form part
of the new mRNA replacing the 24 C-terminus residues present in
CETP with a sequence of 18 residues containing a high concentration
of prolines and positively charged amino acids [1]. Now, the present
study introduces CETPI as a new protein with the potential capability
to recognize, bind and neutralize lipopolysaccharides (LPS) in
Critical Care 2016, 20(Suppl 3):357 Page 196 of 199circulation during septic shock. Employing several peptides derived
from the C-terminus domain of CETPI we demonstrate their property
not only to interact with several LPS serotypes but also to displace
LPS bound to the surface of cells [2].
Results
Peptide VSAK derived from the last 18 residues of CETPI protects
against the cytotoxic effect of LPS upon macrophages, hepatocytes
and microglial cells, does not show cytotoxicity by itself, and pre-
vents against the expression of pro-inflammatory cytokines and the
generation of oxidative stress [2]. For many years, the phenomenon
of recognition of bacterial LPS as components of the cell membrane
of Gram-negative bacteria carried out by the innate immune system
was thought to involve simple pathways if compared to the acquired
immune system. Nowadays this view has dramatically changed since
complex pathways involving multiple receptors and protein-protein
interactions have been described. Nevertheless, despite the efforts
made to counteract what it is known as the inflammatory disequilib-
rium syndrome and overall the outcome of septic shock, current
therapeutic possibilities mainly involving inflammation and metabolic
control and antibiotic treatment, have not changed for many years.
Therefore, since CETPI efficiently binds LPS in vitro and it is overex-
pressed in small intestine cell cultures and proved to be present in
human plasma, the efficacy of the administration of peptide VSAK
against LPS cytotoxicity was studied in vivo. Employing a septic shock
model in rabbits, we demonstrate that the infusion of peptide VSAK
presents the ability to protect against the deleterious effects of LPS
and the property of reducing the presence of TNFα in plasma [2, 3].
Conclusions
CETPI presents itself as a new protein that undoubtedly will advance
the possibilities to better understand and treat the dangerous effects
of LPS present during the treatment of sepsis caused by Gram-
negative bacteria and its common consequence, a septic shock
condition.
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Background
To address the need of more rapid diagnosis of potential pathogens
causing sepsis or septic shock in patients, Q-linea is developing a
fully automated, high-throughput diagnostic platform, ASTrID®.The
system will perform both molecular pathogen identification and
phenotypic antibiotic susceptibility testing (AST), directly from whole
blood, delivering ID after four hours and AST in additional six. The
pathogen panel will cover 95 % of relevant pathogens including 33
unique pathogens and 10 groups, as well as 11 resistance markers.
The panel of antibiotic substances will contain 30 antibiotics and
bacterial growth or inhibition reported as Minimum Inhibitory Con-
centration values.Materials/Methods
In an ongoing study clinical blood samples are collected from pa-
tients suspected of having sepsis attending the Infectious Disease
ER, University hospital of Örebro, Sweden. In addition to the
standard 4 blood culture flasks drawn per patient for routine
diagnostics, an extra, 5–10 ml, blood sample were taken for the
present study. Pathogen ID and AST analysis was performed in a
prototype ASTrID system, starting with target identification
through a proprietary nucleic acid amplification reaction. Highly
specific and selective padlock probes forming circularized DNA
strands [1,2] are amplified via rolling-circle amplification (RCA) [3]
and subsequent circle-to-circle amplification (C2CA) [4]. The
resulting RCA products are labelled with fluorescence and de-
tected on a microarray. The proprietary growth-based AST ana-
lysis was performed on a subset of clinical isolates spiked in
blood (inoculum consistent with 10 CFU/ml blood).
Results
Of the clinical samples collected, 32 samples identified as positive in
normal clinical routine diagnostics were selected and are presented
in this study. Pathogen identification direct from patient in ASTrID
achieved sensitivity of 96 % and specificity of 100 %, compared to
conventional analysis on positive blood culture flasks. When com-
pared with broth microdilution, the ASTrID AST results showed 99 %
essential agreement and 99 % categorical agreement. Overall, the re-
sults were highly correlated with traditional technologies and
EUCAST guidelines.
Conclusion
With ASTrID, both pathogen identification and antibiotic susceptibil-
ity testing can be done within 10 hours from blood draw. This dra-
matically shortens the time to adjusted treatment. The molecular
pathogen identification method allows high multiplex, high sensitiv-
ity testing. The phenotypic antibiotic susceptibility profiling method
developed reports reliable data directly from patient samples, with-
out the need to wait for positive blood cultures. The new ASTrID
platform from Q-linea has the potential to become a crucial tool
against the global challenge of antibiotics resistance, helping to save
lives and reduce healthcare costs.
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Background
Obligate anaerobic bacteria (OAB) are the dominant microflora of
the human body. OAB are often the primary cause of the disease
and can also become aggravating factors. OAB cause extensive
tissue destruction and toxin production that result in multiorgan
failure, thus OAB-associated pathology is usually very difficult to
treat. Mixed behavior of anaerobic-aerobic microflora hampers
the choice of antimicrobials, often OAB are antibiotic-resistant.









Penicillins 65.9 88.5 83.6 26.9
Cephalosporins 29.8 66.8 49.6 31.0
Protected
beta-lactams
18.9 53.2 36.8 15.1
Carbapenems 11.5 22.1 22.7 26.4
Aminoglycosides 29.8 37.9 38.6 17.9
Fluoroquinolones 53.1 73.9 76.4 23.1
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We also evaluated antimicrobial resistance in OAB derived from
blood of patients with diagnosis «sepsis».
Materials and methods
1300 blood samples were incubated under aerobic and anaerobic condi-
tions on “BD Bactec Aerobic/F” and “BD Bactec Anaerobic/F” media re-
spectively in “Bactec 9120” system (“Becton Dickinson”, USA). OAB cultures
were isolated on “Blood Agar” and “Anaerobic Agar” (“Becton Dickinson”,
USA) with 5 % (v/v) whole sheep blood under anaerobic conditions in an-
aerobic environmental chamber “Bactron™” (“Shellab”, USA). Identification
and assessment of sensitivity (resistance) to antibiotics were performed by
means of MALDI-TOF MS and test-systems “API 20A”, “ATB ANA”.
Results
57 cultures of OAB were isolated from 1300 blood samples (4,5 %). 38 OAB
cultures only (67,9 % of OAB isolated) were identified using available tech-
niques of phenotypic identification. 18 OAB cultures (32,1 %) belonged to
Clostridia genus and were identified as C. perfringens (4 cultures), C. sphe-
noides (1), C. acetobutylicum (2), C. fallax (1), C. clostridioforme (1), C. histolyti-
cum (1), C. difficile (3), C. paraputrificum (2), C. butiricum (2), C. novyi (1).
Other 12 Gram-positive OAB cultures (21,4 %) were identified as Eggerthella
lenta (1), Eubacterium lentum (2), E. sabureum (2), Actinomyces naeslundii (1),
Bifidobacterium breve (1), Propionibacterium avidum (1), Peptostreptococcus
anaerobius (1), Anaerococcus prevotii (1), Peptococcus niger (1), P. saccharoly-
ticus (1). 7 Gram-negative OAB cultures (12,5 %) were identified as Bacter-
oides fragilis (1), B. urealyticus (4), Veillonella spp. (2). 30 identified OAB
cultures (78,9 %) were Gram-positive and 8 (21,1 %) – Gram-negative.
Among 18 non-identified OAB cultures (32,1 % of OAB isolated) 12 (66,7 %
of non-identified OAB) were Gram-positive and 6 (33,3 %) – Gram-
negative. 7 OAB cultures (12,5 % of OAB isolated) belonged to C. perfrin-
gens (2), C. acetobutylicum (1), C. fallax (1), E. sabureum (1), E. lentum (1), P.
avidum (1) possessed resistance to metronidazole.
Conclusions
Growing evidence of OAB resistant to conventional antianaerobic drugs
determines the necessity of monitoring resistance of anaerobes.
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Background
Increasing antibiotic resistance of nosocomial pathogens impedes effi-
cient antimicrobial therapy and significantly enhances risk for patients at
early stages after operative treatment [1, 2]. Our aim was to investigate
spectra of clinically relevant pathogens and their antibiotic resistance pat-
terns to validate our current protocols of empiric antibiotic treatment.
Materials and methods
We enrolled 230 patients from a surgical center for coloprotology and
283 patients from a general surgical hospital who had undergone
gastrointestinal surgery and then had a confirmed infectious locus
along with systemic inflammatory response syndrome. 475 blood and
213 abdomen isolates were assessed by MALDI-TOF (Bruker, Germany)
mass-spectrometer and “miniAPI” (“BioMèrieux”, France) analyzer.Results
Both cohorts showed the same structure of blood-derived microorganisms
with 54 % of Gram-positive bacteria. Gram-positive Staphylococcus spp.with
prevalenceof coagulase-negative species andGram-negativeKlebsiella pneu-
moniae dominate in both hospitals. There are statistically significant higher
shares of dominant pathogens in the center for coloproctology: Staphylococ-
cus spp. by 11 %, K. pneumoniae by 5 %; non-fermenting Gram-negative by
4 %. Resistance to penicillins was >70 %; to protected beta-lactams, fluoro-
quinolones and aminoglycosides was >50 %. Mean levels of resistance to
cephalosporins are 79.8 % and 53.2 %, to carbapenems – 42.9 % and 52.9 %
in general vs coloproctological hospitals. Share of blood-derived methicillin-
resistant Staphylococci (MRS) equals >20% inboth hospitals,MRS showed re-
sistance to protected beta-lactams in >90 % cases. Percentage of
vancomycin-resistant Staphylococci is 20.0 % in coloproctology vs 1,4 % in
general clinic. Respectively, blood-derived K. pneumoniae was resistant to
cephalosporins in 63,9% vs 78,2%, to carbapenems – in 33.4% vs 13.5%, to
aminoglycosides – in 68.8 % vs 47.3 %, to fluoroquinolones – in 59.6 % vs
87.2 %. Several tigecycline-resistant blood-derived K. pneumoniae and Acine-
tobacter spp. were isolated. Structure of abdomen-derived isolates is repre-
sented by 47,.2 % of Enterobacteriaceae, 40,.7 % of Gram-positive Cocci and
12.1 % of non-fermenting Gram-negative bacteria. General antibiotic activity
against abdomen-derived microorganisms was 14.3 ± 5,.8 % higher than
against blood-derived. Percentage of abdomen-derived MRS was 52.0 %, re-
sistant to protected beta-lactams – 52.8 %, to vancomycin – 15.1 %, resist-
ance patterns of Gram-negativemicroorganisms see in Table 7.
Conclusions
Our data shows huge burden of resistance with high portion of
strains insusceptible to the last resort antibiotics including tigecyc-
line. Predomination of K. pneumoniae and Pseudomonas aeruginosa
in the structure of Gram-negative bacteraemia corresponds with the
structure of abdominal isolates; higher levels of resistance in blood
isolates compared to abdominal could be driven by selection of re-
sistant strains during systemic antibiotic treatment. Thus strict micro-
biological monitoring is necessary for efficient antibacterial therapy.
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Fig. 17 (abstract P24. Presepsin levels in healthy controls,
nonsurvivors and survivors patients at hospital admission. *p < 0.05
in nonsurvivors vs. survivors at the same time
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Background
To date reliable biomarkers for prognostic evaluation of septic critical pa-
tients, are still needed. A firm pathogenetic and mechanistic association be-
tween a laboratory parameter/mediator and a clinical phenotype is a
necessary assumption to adopt such parameter/mediator as a clinical bio-
marker [1]. CARS phase of sepsis has aroused an increasing interest among
clinicians. In our previous studies, we demonstrated that sCD25 and IL-10 are
reliable sepsis markers [2]. Recently presepsin (soluble CD14 subtype) has
been shown to increase in plasma of septic critical subjects [3]. IL-35, a well
known immunoregulatory cytokine, has been reported among novel sepsis
biomarkers [4]. Aim of this study was the assessment of IL-35 and presepsin
as prognostic sepsismarkers in critical patients.
Materials and methods
For this observational prospective study, were sequentially enrolled crit-
ical patients admitted to the Unit of Intensive Care (ICU) of the University
Hospital of Catanzaro Italy. For such patients admission SOFA scores were
calculated. Based on 28 days survival, subjects were stratified in survivors
(n = 32) and nonsurvivors (n = 17), while a group of healthy volunteers
were also included as negative controls (n = 10). Moreover, clinical and
microbiological data including blood culture were recorded. Plasma and
serum specimens were collected at the patient admission; samples were
tested for presepsin (PATHFAST Presepsin assay), IL-35 (Bio-Ocean LLC)
and procalcitonin (VIDAS B.R.A.H.M.S PCT, bioMérieux, Italy). Data were
subjected to statistical analysis by ANOVA plus post-hoc PLSD Fisher’s
test. Selected data were processed by ROC analysis.
Results
At the admission SOFA scores were found significantly higher (p < 0.001)
in nonsurvivor vs. survivor patients. Admission levels of presepsin were
significantly more elevated (p < 0.05) (Fig. 17), in nonsurvivors vs. survi-
vors at the same time. Presepsin concentrations were found significantly
increased (p < 0.05), in blood culture-positive in comparison to culture-
negative patients at the same time. PCT admission levels did not exhibit
significantly different values between nonsurvivor patients and survivor
subjects. However, culture-positive patients showed PCT levels at admis-
sion significantly increased vs. culture-negative (p < 0.05). Presepsin ad-
mission data from dead/alive individuals were subjected to ROC analysis,
which revealed a very high accuracy and significant AUROCC (p < 0.0001).
Concentrations of IL-35 were found significantly (p < 0.05) higher in
nonsurvivors as well as survivors, when compared with healthy subjects.
Conclusions
Presepsin may substantially improve PCT contribution to clinical decisions in
the patients evaluated. IL-35 appeared a promising future sepsis biomarker,
which deserves further assessment. However present data indicated presep-
sin as a dependable prognostic toolwith an elevated clinical value.References
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Background
Previous studies have shown that during sepsis, brain oxidative stress
and damage are induced by overproduction of reactive oxygen spe-
cies (ROS). Although there are recent reports about the benefits of
statins in experimental sepsis and endotoxemia in peripheral organs,
little is known about its effect in the central nervous system. Our ob-
jective was to investigate the antioxidant properties of simvastatin
and its possible neuroprotective effect during experimental sepsis.
Materials and methods
Male Wistar rats (250–300 g) were submitted to cecal ligation and punc-
ture (CLP, n = 34) or remained as non-manipulated control (or naive, n =
Critical Care 2016, 20(Suppl 3):357 Page 199 of 19934). Both groups were treated by gavage with simvastatin (20 mg/kg) or
an equivalent volume of saline. The animals submitted to CLP were
treated 4 days before and 48 h after surgery. One animal group was de-
capitated and blood and brain were collected to quantify plasma levels
of cytokines and assess astrogliosis and apoptosis in the prefrontal cortex
and hippocampus. Another group was perfused with PBS (0,01 M), and
the same brain structures were dissected to analyze oxidative damage.
Results
The CLP-rats treated with simvastatin showed a reduction in nitric
oxide (P < 0.05), IL1-β (P < 0.001), IL-6 (P < 0.01) and TBARS levels(P < 0.001) and an increase in catalase activity (P < 0.01), citrate
synthase enzyme (P <0.05) and normalized GSH/GSSG ratio. In
addition, the histopathological analysis showed a reduction (P <
0.001) in reactive astrocytes and caspase 3-positive apoptotic
cells.
Conclusions
The results suggest a neuroprotective effect of simvastatin in struc-
tures responsible for the spatial learning and memory. Behavioral
studies are needed to evaluate its impact on cognitive damage trig-
gered by experimental sepsis encephalopathy.•  We accept pre-submission inquiries 
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